Caricamento...
Engineering Solutions for Mitigation of Chimeric Antigen Receptor T-Cell Dysfunction
The clinical successes of chimeric antigen receptor (CAR)-T-cell therapy targeting cell surface antigens in B cell leukaemias and lymphomas has demonstrated the proof of concept that appropriately engineered T-cells have the capacity to destroy advanced cancer with long term remissions ensuing. Neve...
Salvato in:
| Pubblicato in: | Cancers (Basel) |
|---|---|
| Autori principali: | , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
MDPI
2020
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7463974/ https://ncbi.nlm.nih.gov/pubmed/32824734 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12082326 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|